Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinuvel PharmaceuticalsCLVLF 92 Equity-to-Asset is 0.92 as of Dec. 2025, which is 2% above its 10-year median of 0.90. GuruFocus rates CLVLF with a GF Score™ of 92/100 and a GF Value™ of $11.76 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 87.92% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Clinuvel Pharmaceuticals Equity-to-Asset Related Terms
Clinuvel Pharmaceuticals Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLVLF vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Clinuvel Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals (CLVLF) has a Equity-to-Asset of 0.92 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Clinuvel Pharmaceuticals and its competitors. This is near median its historical median of 0.90. Over the past decade, Clinuvel Pharmaceuticals' Equity-to-Asset has ranged from 0.84 to 0.94. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #171 out of 1416 companies in the Biotechnology industry, placing it in the top 12.1%.
Is Clinuvel Pharmaceuticals' Equity-to-Asset too high?
Clinuvel Pharmaceuticals' current Equity-to-Asset of 0.92 is near median its 10-year median of 0.90. Over the past 10 years, this metric has ranged from a low of 0.84 to a high of 0.94. The Biotechnology industry median Equity-to-Asset is 0.68. Clinuvel Pharmaceuticals' value of 0.92 is 35.3% above this industry median. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #171 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 92/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #171 out of 1416 companies for Equity-to-Asset. This places Clinuvel Pharmaceuticals in the top 12% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Clinuvel Pharmaceuticals' value of 0.92 is 35.3% above this benchmark. Historically, Clinuvel Pharmaceuticals' own Equity-to-Asset has ranged from 0.84 to 0.94 over the past decade. While the company's 10-year median is 0.90 vs. the industry median of 0.68, Clinuvel Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinuvel Pharmaceuticals's current Equity-to-Asset of 0.92 is 35.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Clinuvel Pharmaceuticals and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinuvel Pharmaceuticals's current Equity-to-Asset is 0.92, which is near median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (CLVLF) is currently considered Significantly Undervalued. The stock's GF Value™ is $11.76, compared to a current price of $6.37 — trading 45.8% below its estimated fair value. The current Equity-to-Asset is 0.92, which is near median its 10-year median of 0.90 and 35.3% above the Biotechnology industry median of 0.68. Clinuvel Pharmaceuticals' overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (CLVLF), the current Equity-to-Asset is 0.92 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (CLVLF) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of $6.37 is trading 45.8% below its estimated GF Value™ of $11.76.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for CLVLF:
Equity-to-Asset: 0.92 (near median its 10-year median of 0.90)
GF Value™: $11.76 vs. price of $6.37 (45.8% below fair value)
Industry Position: 35.3% above the Biotechnology median (#171 of 1416)
No single metric tells the full story. See the CLVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
92GF Score
Get the complete analysis for CLVLF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLVLF has been successfully added to your 
